Drug Profile
Psilocybin - COMPASS Pathways
Alternative Names: COMP-360; PsilocybineLatest Information Update: 05 Mar 2024
Price :
$50
*
At a glance
- Originator COMPASS Pathways
- Developer COMPASS Pathways; Imperial College of Science, Technology and Medicine; Johns Hopkins University
- Class Analgesics; Anti-infectives; Anti-inflammatories; Antidepressants; Antineoplastics; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Indoles; Mood stabilisers; Neuropsychotherapeutics; Organophosphorus compounds; Phytotherapies; Small molecules
- Mechanism of Action ATP-binding cassette transporter modulators; Serotonin 5-HT2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Depressive disorders
- Phase II Anorexia nervosa; Bipolar depression; Major depressive disorder; Post-traumatic stress disorders; Somatoform disorders
- Phase Unknown Pervasive child development disorders
Most Recent Events
- 14 Feb 2024 Phase-III clinical trials in Depressive disorders (Treatment-resistant) in Spain, Ireland, Canada (PO) (NCT05711940)
- 20 Dec 2023 Efficacy data from a phase II trial in Major depressive disorder released
- 19 Dec 2023 Adverse events data from a phase II trial in Post-traumatic stress disorders released by Compass Pathways